What Macmiror Complex 500 Treats: Main Uses and Benefits

The combination therapy is commonly used across domains where additional symptomatic support is needed for vulvovaginal infections. Its primary application is the polyvalent therapy of diseases caused by pathogenic microorganisms. It is applied in addressing conditions associated with a broad range of microbial types, including bacterial, protozoal, and fungal manifestations, such as those seen in Mixed Vaginitis (MV), Bacterial Vaginosis (BV), or Vulvovaginal Candidiasis (VVC).

This therapy is relevant in contexts involving heightened systemic burden or acute symptom patterns. It assists with managing symptom clusters related to inflammatory or irritative states, such as abnormal discharge, itching, burning, and localized inflammation. This broad approach assists with managing symptoms that interfere with daily functioning in scenarios where the exact cause may not be immediately clear. The treatment supports symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Symptomatic Support

This therapy is used in situations involving certain distressing symptoms and helps address symptom clusters that may become intense or disruptive. It provides support that helps ease the overall symptom burden.

Regulatory References

1. Agenzia Italiana del Farmaco (AIFA) product information

Eligibility Scope

Absolute Contraindication The medicine is strictly contraindicated for patients with a known history of hypersensitivity or allergy to either of the active ingredients—Nifuratel and Nystatin—or any other components of the vaginal ovule formulation.

Age-Related Eligibility The product indication is officially restricted to adult women. Safety and effectiveness in the pediatric population (children and adolescents) have not been formally established by regulatory bodies, and use is therefore not recommended. No specific precautions are generally noted for the geriatric population.

Special Physiological Status Use during pregnancy is classified as conditional and is only permitted when deemed essential by a healthcare provider, or when the potential clinical benefit is considered to outweigh any possible risk. Caution is recommended when prescribing to women who are breastfeeding due to a lack of data on drug excretion into human milk.

Eligibility Classification

This official profile is defined by Absolute Exclusion (Hypersensitivity) and Conditional Restriction (Pregnancy/Lactation), reflecting the strict population boundaries established in the Summary of Product Characteristics (SmPC) from national regulatory authorities.

Interactions with other medicines and products

The official interaction profile for Macmiror Complex 500 is determined by its local route of administration. Since the active components, Nifuratel and Nystatin, demonstrate negligible systemic absorption into the bloodstream, the potential for systemic drug-drug interactions is minimal.

Authoritative regulatory documents confirm that systemic pharmacokinetic interactions, including those involving enzyme-mediated effects or alterations to drug plasma concentrations, are not known. There are no co-administered medicinal products explicitly listed as contraindicated due to a systemic interaction with this therapy.

The only officially documented interaction is a local, physical constraint related to the formulation's excipients. The fatty components of the vaginal ovule can compromise the structural integrity of medical devices made from latex or rubber, such as certain barrier contraceptives (condoms or diaphragms). This physical interaction can lead to the device's failure or loss of function.

Due to this documented restriction, the use of latex or rubber barrier contraceptives must be avoided throughout the course of treatment. Regulatory prescribing information contains no specific documented interactions with food, alcohol, or herbal products.

Intracellular Destruction of Pathogen DNA and Metabolism

The component Nifuratel acts by engaging microbial nitroreductase enzymes—present only in bacteria, protozoa, and certain fungi—to transform the drug into highly reactive intermediates. These intermediates then damage the pathogen's DNA and inhibit vital metabolic enzymes, initiating a lethal process that leads to microbial death (bactericidal and trichomonacidal activity). The mechanism demonstrates selective action, failing to activate the drug in most host cells or protective Lactobacillus species.

---

Physical Lysis of Fungal Cell Membranes

The component Nystatin exerts antifungal action characterized by specific binding to ergosterol, the primary sterol in fungal membranes. This binding immediately creates transmembrane pores or channels, causing the uncontrolled leakage of essential intracellular contents, such as potassium ions. This immediate loss of osmotic integrity results in swift fungal cell lysis and death (fungicidal activity). The fungicidal activity results in the physical destruction of the Candida cell component.

---

Comprehensive Pathogen Clearance through Dual Synergy

The combination establishes polyvalent microbial control, covering multiple classes of microorganisms implicated in local microbial imbalances. While Nifuratel covers bacteria, protozoa, and certain fungi via intracellular chemical disruption, Nystatin facilitates physical destruction against fungi. This dual-mechanistic process facilitates the comprehensive clearance of the microbial load. The clearance of pathogenic organisms creates conditions for the restoration of the local microbial environment.

How to Use Macmiror Complex 500

Macmiror Complex 500 is a vaginal capsule containing the active substances Nifuratel (500 mg) and Nystatin (200,000 IU), indicated for the local treatment of vaginal and vulval infections caused by susceptible microorganisms, including Candida and Trichomonas species, as well as bacteria.

Administration and Dosage

The medicine is for vaginal use only. It must not be taken by mouth. The typical adult dosage is generally one vaginal capsule daily, usually administered in the evening before sleep.

Step	Instruction
1. Preparation	Wash your hands thoroughly before use.
2. Insertion	Lie on your back with your knees bent.
3. Application	Insert the soft vaginal capsule (ovule) as deep as possible into the vagina to ensure optimal therapeutic effect.
4. Completion	Continue the full course of treatment as prescribed by your healthcare provider, typically for a period of 8 days, even if symptoms improve or if menstruation begins.

Important Considerations

• Do not interrupt treatment during menstruation.
• To prevent re-infection, sexual intercourse should be avoided during treatment, or barrier methods should be used.
• If you are pregnant, consult your doctor regarding the use of the ovule and the method of insertion.
• A sanitary pad may be worn to protect clothing from minor discharge or capsule residue. If symptoms worsen or do not improve after the treatment course, consult your healthcare provider.

Research evidence / Overview of Studies for Macmiror Complex 500

---

Evidence for Use in Mixed Vaginal Infections

Research for Macmiror Complex 500 has been conducted to examine its application in mixed vaginal infections. These are conditions characterized by fluctuating or episodic manifestations often including the concurrent presence of various pathogens, such as bacteria, fungi (Candida), and protozoa (Trichomonas). Studies in this area include Randomized Controlled Trials (RCTs) and systematic reviews, which compared the combination therapy against other forms of local treatment.

This research examined outcomes related to physical discomfort and whether the targeted organisms achieved microbiological negativization. Studies monitored two main factors: the rate of clinical cure, meaning how the patient's symptoms evolved and changed over time, and the rate of microbiological negativization, which is laboratory evidence that the infection-causing organisms were no longer detected. Findings describe patterns related to the use of this combination in women with these multi-pathogen conditions. Reported data describe patterns related to symptom evolution and clearance rates, which were often compared against other local therapeutic options within the study design.

---

Evidence for Component-Specific Vaginal Infections

In addition to mixed infections, this therapy was studied for its use in conditions where one pathogen is dominant, such as Bacterial Vaginosis (BV), certain cases of Vulvovaginal Candidiasis (VVC), and Trichomonal Vaginitis (TV). The research here includes controlled clinical trials where the combination was observed in adult women with these specific diagnoses. Studies explored outcomes linked to inflammatory or irritative states, such as the rate of pathogen clearance and symptom change, compared to other local monotherapies.

Long-Term Evidence and Durability of Effect

Clinical research on this therapy typically focuses on short-term outcomes capturing phases of heightened symptom activity. Studies monitored for a return of the infection, known as recurrence, usually within one month after the final dose. Long-term effects are not fully established. Follow-up durations were limited in many of the key studies, meaning the data available provides limited insight into whether the effects are durable or if they prevent future recurrences over an extended period.

Evidence in Special Populations Studied

The available research provides some specific information regarding its use in certain populations, particularly pregnant women. This special population was evaluated in specific clinical trials focusing on mixed vaginal infections. However, limited information is available for certain groups beyond this population. For instance, there is little published evidence about the use of this specific combination in older adults or in women with certain underlying health conditions (comorbidities).

Clarity and Uncertainty in the Research Landscape

Key limitations in the current research base include the methodological heterogeneity across published trials. Additionally, comparative evidence against all current gold standard local therapies is lacking, as trials often focus on comparison with older or single-agent alternatives. Therefore, research is ongoing in this area, and a documented need for larger, highly standardized clinical trials remains to provide the highest level of certainty regarding long-term outcomes and performance across diverse groups. Study results reflect the specific conditions under which they were conducted and findings describe group patterns, not personal outcomes.

Common questions about Macmiror Complex 500 (FAQ)

Q: What are the signs of an allergic reaction to Macmiror Complex 500?

Regulatory documents describe systemic reactions, including severe hypersensitivity, as being classified in the Very Rare or Not Known frequency categories. Local reactions such as burning, itching (pruritus), or redness (erythema) are listed as uncommon side effects. The medicine is strictly contraindicated for individuals with a known allergy to its active components or excipients.

Q: When is the full benefit of Macmiror Complex 500 typically expected?

The treatment is typically prescribed for a specific duration, such as 8 days. While an official time for the onset of full effect may not be stated, clinical benefit is associated with the completion of the prescribed treatment course. This benefit involves the resolution of symptoms and clearance of the targeted microorganisms.

Q: Are there any known interactions between Macmiror Complex 500 and alcohol consumption?

The official interaction profile states that systemic interactions with alcohol are not known or not reported, given the localized administration. However, a high-level caution is included regarding the potential for a Disulfiram-like reaction due to the Nifuratel component.

Q: Are there any specific lifestyle activities to avoid while using Macmiror Complex 500?

Regulatory documents explicitly advise that sexual intercourse should be avoided throughout the treatment period. Additionally, the use of latex or rubber barrier contraceptives must be avoided. These precautions are advised to avoid the possibility of re-infection or compromising the physical integrity of barrier contraceptives.

Q: How does the medicine work to prevent infections from coming back?

The medicine’s dual mechanism provides comprehensive clearance of pathogens (bacteria, fungi, and protozoa), which supports the restoration of the local microbial environment. This action is critical for recovery and minimizing the risk of recurrence. Official research primarily focuses on short-term efficacy and monitored for recurrence within a limited period after treatment.

Q: Does Macmiror Complex 500 treat only specific types of bacterial infections or a wider range?

Official documents confirm the Nifuratel component provides a broad antibacterial spectrum, active against a wide range of bacteria, including both aerobic and anaerobic types. The drug is classified for 'polyvalent microbial control,' referencing its activity against multiple types of microorganisms simultaneously.

Q: What are the general expectations for recovery described in official documents after using this medicine?

Recovery is generally associated with the resolution of symptoms and microbiological clearance. Symptom improvement is generally monitored throughout the typical treatment course. Official patient information advises consulting a healthcare provider if symptoms worsen or do not show improvement after the full treatment course.

Q: Are there any known long-term side effects associated with Macmiror Complex 500?

Regulatory data emphasizes the drug's localized action and negligible absorption into the bloodstream. Research evidence indicates that studies often focused on short-term outcomes. Therefore, data regarding long-term effects is limited, as follow-up periods in many studies were generally brief.

Q: Can Macmiror Complex 500 be used by someone with a history of liver issues?

Due to the medicine’s localized administration and minimal absorption into the bloodstream, regulatory documents typically do not list specific safety constraints related to kidney or liver impairment. Individual circumstances, including a history of liver issues, require consideration by a healthcare professional.

Q: What happens if a person misses a single dose of Macmiror Complex 500?

Official patient information may describe a procedure for a missed dose, which typically involves taking the dose as soon as it is remembered, unless the next dose is due shortly thereafter. It is also generally advised not to take a double dose to make up for the missed one. Continuing the full prescribed course is typically emphasized.

Q: Can Macmiror Complex 500 be used by people who have allergies to other topical medicines?

Regulatory contraindications (reasons the drug must not be used) are strictly limited to a known allergy to the active ingredients Nifuratel, Nystatin, or any excipients in the ovule. Allergies to other topical medications that are not related to the active components are not cited as a strict contraindication in the official product information.

Q: Does Macmiror Complex 500 contain any steroids?

The official composition of Macmiror Complex 500 lists the active ingredients as Nifuratel and Nystatin. Since no corticosteroids (steroids) are listed in the product description as active components, the medicine does not contain them.

Q: What is the typical appearance of the Macmiror Complex 500 medicine?

The official product characteristics describe the medicine as a soft vaginal capsule, often referred to as an ovule. It is typically described as being egg-shaped and having a distinct yellowish-brown color.

Q: How soon after finishing Macmiror Complex 500 can intimate activities typically resume?

While specific regional documents may vary, patient information leaflets often recommend a waiting period, such as 3 days following the final dose, before resuming intimate activities. This recommended period supports the full efficacy of the treatment and aims to minimize the risk of re-infection.

Storage and Disposal Requirements for Macmiror Complex 500

The storage and handling of Macmiror Complex 500 vaginal ovules are subject to specific regulatory constraints to ensure stability and safety.

Official Storage Conditions

Macmiror Complex 500 must be stored at a temperature below 25 C and has an official shelf life of 36 months when maintained under this condition. It is a mandatory requirement to keep the medicine out of the sight and reach of children to prevent accidental exposure. The product must not be used after the expiration date printed on the packaging.

Disposal Instructions

Official regulations require that unused or expired Macmiror Complex 500 must not be disposed of via wastewater or household waste containers. To ensure proper environmental and controlled waste management, patients must be advised to ask their pharmacist how to dispose of any medicine that is no longer needed.